Search Results: Treatment + Pancreatic Cancer (16 results)
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
https://www.facingourrisk.org/research-clinical-trials/study/356/treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies
Treatment
Treatment study for people with advanced or metastatic cancers
This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.
Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib
Treatment
Treatment study for people with advanced or metastatic cancers
This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.
Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors
The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations.
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (LAP100)
https://www.facingourrisk.org/research-clinical-trials/study/347/testing-higher-dose-radiation-therapy-for-locally-advanced-pancreatic-cancer
Treatment
Radiation treatment study for people with locally advanced pancreatic cancer
This research study will test whether higher doses of radiation therapy are safe and effective for people with locally advanced pancreatic cancer.
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350/treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Treatment
Treatment study for people with advanced or metastatic solid tumors
The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor.
Study of the drug TNG260 and an Immunotherapy in Advanced Solid Tumors With a STK11 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/333/study-of-the-drug-tng260-and-an-immunotherapy-in-advanced-solid-tumors-with-a-stk11-mutation
Treatment
This is a treatment study enrolling people with advanced or metastatic solid tumors with known STK11 mutations
The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.
Treating Metastatic Pancreatic Cancer Using a New Combination of Chemotherapy Drugs in People with a BRCA1, BRCA2 or PALB2 genetic or tumor mutation (The PLATINUM Trial)
https://www.facingourrisk.org/research-clinical-trials/study/338/treating-metastatic-brca1-brca2-or-palb2-pancreatic-cancer-using-a-new-combination-of-chemotherapy-drugs
Treatment
Treatment study for people with metastatic pancreatic cancer and a BRCA1, BRCA2 or PALB2 mutation
This study will compare a 3-drug chemotherapy combination (NABPLAGEM; gemcitabine, cisplatin, nab-paclitaxel) to a 2-drug chemotherapy combination (gemcitabine/nab-paclitaxel) to treat people with an inherited and/or tumor-associated BRCA1, BRCA2 or PALB2 mutation who have pancreatic cancer that has progressed on front-line treatment with FOLFIRINOX/NALIRIFOX (fluorouracil, irinotecan, leucovorin and oxaliplatin).
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas.
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)
https://www.facingourrisk.org/research-clinical-trials/study/140/olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation
Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation
The usual approach for patients with curable (i.e., non-metastatic) pancreatic cancer is a combination of surgery, FDA-approved chemotherapy, radiation (in select cases), then surveillance monitoring. This means that patients are typically monitored by their oncologist for evidence that the cancer has returned (recurrence), but they receive no additional treatment after the completion of surgery and chemotherapy.
The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with a drug called olaparib, in patients with BRCA1, BRCA2 or PALB2 mutation. EA2192 / APOLLO will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if olaparib delays cancer recurrence compared to the usual approach of surveillance.
Treating Metastatic Breast or Pancreatic Cancer in People with an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Treatment study for metastatic breast or pancreatic cancer in people with an inherited BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation
https://www.facingourrisk.org/research-clinical-trials/study/164/adding-pembrolizumab-to-olaparib-to-treat-pancreatic-cancer-in-people-with-an-inherited-brca-mutation
Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation
This study is researching whether adding the immunotherapy drug Pembrolizumab (Keytruda) to the PARP inhibitor Olaparib (Lynparza) works better than olaparib alone in treating people with metastatic pancreatic cancer who also have an inherited BRCA1 or BRCA2 mutation.
Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
Additional Results on Clinicaltrials.gov Treatment + Pancreatic Cancer
124 results
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT ID: NCT04119024 (https://clinicaltrials.gov/study/NCT04119024)
24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
NCT ID: NCT07043270 (https://clinicaltrials.gov/study/NCT07043270)
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT ID: NCT05411094 (https://clinicaltrials.gov/study/NCT05411094)
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
NCT ID: NCT06411795 (https://clinicaltrials.gov/study/NCT06411795)
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://clinicaltrials.gov/study/NCT04222413)
Use Of Indocyanine Green In Pancreas Surgery
NCT ID: NCT06084013 (https://clinicaltrials.gov/study/NCT06084013)
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
NCT ID: NCT03334708 (https://clinicaltrials.gov/study/NCT03334708)
Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
NCT ID: NCT05132504 (https://clinicaltrials.gov/study/NCT05132504)
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
NCT ID: NCT07148128 (https://clinicaltrials.gov/study/NCT07148128)
Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples from Colorectal Cancer Patients
NCT ID: NCT00899626 (https://clinicaltrials.gov/study/NCT00899626)
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
NCT ID: NCT03322995 (https://clinicaltrials.gov/study/NCT03322995)
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
NCT ID: NCT06698458 (https://clinicaltrials.gov/study/NCT06698458)
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
NCT ID: NCT04683315 (https://clinicaltrials.gov/study/NCT04683315)
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT ID: NCT06989437 (https://clinicaltrials.gov/study/NCT06989437)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://clinicaltrials.gov/study/NCT05417594)
The Seven Trial: Exploiting the Unfolded Protein Response
NCT ID: NCT06076837 (https://clinicaltrials.gov/study/NCT06076837)
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
NCT ID: NCT06704724 (https://clinicaltrials.gov/study/NCT06704724)
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
NCT ID: NCT05013216 (https://clinicaltrials.gov/study/NCT05013216)
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
NCT ID: NCT04858009 (https://clinicaltrials.gov/study/NCT04858009)
Pancreatic Cancer & Surgical Resection
NCT ID: NCT05170802 (https://clinicaltrials.gov/study/NCT05170802)
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)
Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer
NCT ID: NCT06984562 (https://clinicaltrials.gov/study/NCT06984562)
Phase I/IB Trial of Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
NCT ID: NCT06141031 (https://clinicaltrials.gov/study/NCT06141031)
Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
NCT ID: NCT04789486 (https://clinicaltrials.gov/study/NCT04789486)
Stereotactic Magnetic Resonance Guided Radiation Therapy
NCT ID: NCT04115254 (https://clinicaltrials.gov/study/NCT04115254)
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
NCT ID: NCT04485286 (https://clinicaltrials.gov/study/NCT04485286)
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
NCT ID: NCT05799274 (https://clinicaltrials.gov/study/NCT05799274)
ExoLuminate Study for Early Detection of Pancreatic Cancer
NCT ID: NCT05625529 (https://clinicaltrials.gov/study/NCT05625529)
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
NCT ID: NCT06593431 (https://clinicaltrials.gov/study/NCT06593431)
Intravital Microscopy in Human Solid Tumors
NCT ID: NCT03823144 (https://clinicaltrials.gov/study/NCT03823144)
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
NCT ID: NCT03257033 (https://clinicaltrials.gov/study/NCT03257033)
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
NCT ID: NCT01365169 (https://clinicaltrials.gov/study/NCT01365169)
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
NCT ID: NCT03551951 (https://clinicaltrials.gov/study/NCT03551951)
Brodalumab in the Treatment of Immune-Related Adverse Events
NCT ID: NCT06673329 (https://clinicaltrials.gov/study/NCT06673329)
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
NCT ID: NCT04115163 (https://clinicaltrials.gov/study/NCT04115163)
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
NCT ID: NCT05517811 (https://clinicaltrials.gov/study/NCT05517811)
Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas
NCT ID: NCT02598349 (https://clinicaltrials.gov/study/NCT02598349)
An Observational Research Study to Uncover Subtypes of Cancer Cachexia
NCT ID: NCT06073431 (https://clinicaltrials.gov/study/NCT06073431)
Comparison Of Radiation Exposure To Patients During Endoscopic Retrograde Cholangiopancreatography (ERCP) Performed By Endoscopists Trained In Judicious Use Of Fluoroscopy With Those Without Formal Training
NCT ID: NCT03525353 (https://clinicaltrials.gov/study/NCT03525353)
The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
NCT ID: NCT06843551 (https://clinicaltrials.gov/study/NCT06843551)
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
NCT ID: NCT04157127 (https://clinicaltrials.gov/study/NCT04157127)
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
NCT ID: NCT06001268 (https://clinicaltrials.gov/study/NCT06001268)
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
NCT ID: NCT07118176 (https://clinicaltrials.gov/study/NCT07118176)
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT ID: NCT05040360 (https://clinicaltrials.gov/study/NCT05040360)
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
NCT ID: NCT02757859 (https://clinicaltrials.gov/study/NCT02757859)
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT06625320 (https://clinicaltrials.gov/study/NCT06625320)
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
NCT ID: NCT06454383 (https://clinicaltrials.gov/study/NCT06454383)
Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer
NCT ID: NCT05296421 (https://clinicaltrials.gov/study/NCT05296421)
Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer
NCT ID: NCT05911243 (https://clinicaltrials.gov/study/NCT05911243)
Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma
NCT ID: NCT05241249 (https://clinicaltrials.gov/study/NCT05241249)
Lidocaine Infusion in Pancreatic Cancer
NCT ID: NCT04048278 (https://clinicaltrials.gov/study/NCT04048278)
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
NCT ID: NCT03652428 (https://clinicaltrials.gov/study/NCT03652428)
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
NCT ID: NCT04275557 (https://clinicaltrials.gov/study/NCT04275557)
Pilot Study of Pancreatic Cancer Screening
NCT ID: NCT05058846 (https://clinicaltrials.gov/study/NCT05058846)
The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT ID: NCT02000089 (https://clinicaltrials.gov/study/NCT02000089)
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT05723107 (https://clinicaltrials.gov/study/NCT05723107)
Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer
NCT ID: NCT06639724 (https://clinicaltrials.gov/study/NCT06639724)
Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer
NCT ID: NCT03260842 (https://clinicaltrials.gov/study/NCT03260842)
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
NCT ID: NCT05687123 (https://clinicaltrials.gov/study/NCT05687123)
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
NCT ID: NCT04975217 (https://clinicaltrials.gov/study/NCT04975217)
Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
NCT ID: NCT01416714 (https://clinicaltrials.gov/study/NCT01416714)
Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations
NCT ID: NCT05687188 (https://clinicaltrials.gov/study/NCT05687188)
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
NCT ID: NCT06423326 (https://clinicaltrials.gov/study/NCT06423326)
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://clinicaltrials.gov/study/NCT05837767)
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
NCT ID: NCT04638751 (https://clinicaltrials.gov/study/NCT04638751)
Autologous CAR-T Cells Targeting B7-H3 in PDAC
NCT ID: NCT06158139 (https://clinicaltrials.gov/study/NCT06158139)
UCSF PANC Cyst Registry
NCT ID: NCT04291651 (https://clinicaltrials.gov/study/NCT04291651)
Exosomal miRNA Liquid Biopsy for Early Liver Metastasis Detection in Pancreatic Cancer
NCT ID: NCT07224802 (https://clinicaltrials.gov/study/NCT07224802)
Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT ID: NCT03991962 (https://clinicaltrials.gov/study/NCT03991962)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://clinicaltrials.gov/study/NCT04550494)
Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
NCT ID: NCT05764720 (https://clinicaltrials.gov/study/NCT05764720)
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
NCT ID: NCT05975593 (https://clinicaltrials.gov/study/NCT05975593)
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT ID: NCT02584244 (https://clinicaltrials.gov/study/NCT02584244)
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
NCT ID: NCT05685602 (https://clinicaltrials.gov/study/NCT05685602)
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
NCT ID: NCT03977233 (https://clinicaltrials.gov/study/NCT03977233)
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
NCT ID: NCT03384238 (https://clinicaltrials.gov/study/NCT03384238)
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT ID: NCT05477576 (https://clinicaltrials.gov/study/NCT05477576)
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT ID: NCT06958328 (https://clinicaltrials.gov/study/NCT06958328)
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
NCT ID: NCT05053971 (https://clinicaltrials.gov/study/NCT05053971)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT ID: NCT05379985 (https://clinicaltrials.gov/study/NCT05379985)
The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
NCT ID: NCT04406831 (https://clinicaltrials.gov/study/NCT04406831)
Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery
NCT ID: NCT06731998 (https://clinicaltrials.gov/study/NCT06731998)
PHL Treatment in Pancreatic Cancer
NCT ID: NCT05365893 (https://clinicaltrials.gov/study/NCT05365893)
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
NCT ID: NCT06381154 (https://clinicaltrials.gov/study/NCT06381154)
Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
NCT ID: NCT04975516 (https://clinicaltrials.gov/study/NCT04975516)
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT07252232 (https://clinicaltrials.gov/study/NCT07252232)
PANCREATIC DISEASE COHORT A Registry and Biospecimen Bank to Better Understand Pancreatic Disease
NCT ID: NCT01102556 (https://clinicaltrials.gov/study/NCT01102556)
A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
NCT ID: NCT06151223 (https://clinicaltrials.gov/study/NCT06151223)
A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
NCT ID: NCT05830097 (https://clinicaltrials.gov/study/NCT05830097)
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
NCT ID: NCT04005690 (https://clinicaltrials.gov/study/NCT04005690)
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
NCT ID: NCT04858334 (https://clinicaltrials.gov/study/NCT04858334)
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
NCT ID: NCT03492671 (https://clinicaltrials.gov/study/NCT03492671)
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT ID: NCT05733000 (https://clinicaltrials.gov/study/NCT05733000)
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT ID: NCT02838836 (https://clinicaltrials.gov/study/NCT02838836)
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
NCT ID: NCT06782932 (https://clinicaltrials.gov/study/NCT06782932)
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
NCT ID: NCT06850623 (https://clinicaltrials.gov/study/NCT06850623)
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
NCT ID: NCT05518903 (https://clinicaltrials.gov/study/NCT05518903)
High Dose Omeprazole in Patients With Pancreatic Cancer
NCT ID: NCT04930991 (https://clinicaltrials.gov/study/NCT04930991)
Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-
NCT ID: NCT06937996 (https://clinicaltrials.gov/study/NCT06937996)
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
NCT ID: NCT03704662 (https://clinicaltrials.gov/study/NCT03704662)
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
NCT ID: NCT05679674 (https://clinicaltrials.gov/study/NCT05679674)
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
NCT ID: NCT05624918 (https://clinicaltrials.gov/study/NCT05624918)
Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT
NCT ID: NCT06412510 (https://clinicaltrials.gov/study/NCT06412510)
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
NCT ID: NCT01915225 (https://clinicaltrials.gov/study/NCT01915225)
Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer
NCT ID: NCT06736717 (https://clinicaltrials.gov/study/NCT06736717)
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
NCT ID: NCT06630325 (https://clinicaltrials.gov/study/NCT06630325)
Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resectable Pancreatic Cancer
NCT ID: NCT05836870 (https://clinicaltrials.gov/study/NCT05836870)
Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas Cancer
NCT ID: NCT06205849 (https://clinicaltrials.gov/study/NCT06205849)
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
NCT ID: NCT06600906 (https://clinicaltrials.gov/study/NCT06600906)
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
NCT ID: NCT05462496 (https://clinicaltrials.gov/study/NCT05462496)
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://clinicaltrials.gov/study/NCT04150042)
Intraoperative Radiation Therapy After Stereotactic Body Radiation Therapy and Chemotherapy in Treatment of Pancreatic Adenocarcinoma
NCT ID: NCT05141513 (https://clinicaltrials.gov/study/NCT05141513)
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
NCT ID: NCT06651580 (https://clinicaltrials.gov/study/NCT06651580)
Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
NCT ID: NCT05961982 (https://clinicaltrials.gov/study/NCT05961982)
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
NCT ID: NCT04340141 (https://clinicaltrials.gov/study/NCT04340141)
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
NCT ID: NCT04484909 (https://clinicaltrials.gov/study/NCT04484909)
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence
NCT ID: NCT06228599 (https://clinicaltrials.gov/study/NCT06228599)
The Vanguard Study: Testing a New Way to Screen for Cancer
NCT ID: NCT06995898 (https://clinicaltrials.gov/study/NCT06995898)
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
NCT ID: NCT04172532 (https://clinicaltrials.gov/study/NCT04172532)
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT ID: NCT06447662 (https://clinicaltrials.gov/study/NCT06447662)
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
NCT ID: NCT06807437 (https://clinicaltrials.gov/study/NCT06807437)
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
NCT ID: NCT04851119 (https://clinicaltrials.gov/study/NCT04851119)
Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma
NCT ID: NCT06831136 (https://clinicaltrials.gov/study/NCT06831136)
Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source
NCT ID: NCT02843945 (https://clinicaltrials.gov/study/NCT02843945)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.